Agents for in vivo control of adult stem cells

成体干细胞体内控制剂

基本信息

  • 批准号:
    7230165
  • 负责人:
  • 金额:
    $ 14.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-01 至 2008-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mesenchymal stem cells from bone marrow stroma are pluripotent and can be expanded ex vivo whilst retaining their multi-potentiality. They therefore provide a convenient ex vivo model for the study of mesenchymal stem cell differentiation. More specifically, the process of stem cell proliferation coupled to osteoblastic differentiation can be closely monitored, permitting the detailed investigation of osteogenic tissue repair in an experimentally accessible model. This research plan describes an investigation designed to discover and evaluate compounds that reverse the effect of Dkk-1 thereby activating the canonical Wnt signaling pathway. This would therefore increase the rate of osteogenic differentiation by MSCs. This proposal tests the central hypothesis that small molecules may have utility in improving osteogenic tissue repair by MSCs in bone degenerative diseases such as multiple myeloma and osteogenesis imperfecta. These molecules could contribute to the development of a novel family of pharmaceutically active agents for the improvement of the natural healing process in humans. There are 3 Specific Aims: 1 To investigate the effect of the canonical Wnt inhibitor dickkopf-1 and glycogen-synthase-kinase-3-beta (GSKSb) inhibitors on osteogenic differentiation by mesenchymal stem cells in vitro. 2 To optimize a murine model of multiple myeloma that exhibit osteolytic lesions and to test known GSKSb inhibitors for utility in reducing the formation of osteolytic lesions. 3 To test the utility of in enhancing osteogenic tissue repair in a murine model of osteogenesis imperfecta. Adult stem cells have the potential to dramatically improve regenerative medicine in the future. This proposal is designed to discover molecules that improve the inherent capacity of adult human stem cells to repair bone tissue. These molecules are clinically relevant for the treatment of diseases such as Osteogenesis Imperfecta (brittle bone disease) and malignant bone disease and critical size bone injuries.
描述(由申请人提供):来自骨髓基质的间充质干细胞是多能的,并且可以离体扩增,同时保留其多潜能性。因此,它们为间充质干细胞分化的研究提供了方便的离体模型。更具体地说,可以密切监测干细胞增殖与成骨细胞分化的过程,从而可以在实验可获得的模型中详细研究成骨组织修复。该研究计划描述了一项旨在发现和评估逆转Dkk-1效应从而激活经典Wnt信号通路的化合物的研究。因此,这将增加MSC的成骨分化速率。该提案测试了核心假设,即小分子可能有助于改善骨髓间充质干细胞在多发性骨髓瘤和成骨不全症等骨退行性疾病中的成骨组织修复。这些分子可能有助于开发一种新的药物活性剂家族,以改善人类的自然愈合过程。有三个具体目标: 1研究经典Wnt抑制剂dickkopf-1和糖原合成酶激酶3 β(GSKSb)抑制剂对骨髓间充质干细胞体外成骨分化的影响。 2优化多发性骨髓瘤的小鼠模型,表现出溶骨性病变,并测试已知的GSKSb抑制剂在减少溶骨性病变形成中的效用。 3在小鼠成骨缺损模型中,测试在促进成骨组织修复中的效用。 成体干细胞有潜力在未来大大改善再生医学。这项提议旨在发现提高成人干细胞修复骨组织的内在能力的分子。这些分子在临床上与诸如成骨不全(脆骨病)和恶性骨疾病以及临界尺寸骨损伤的疾病的治疗相关。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.
DKK-1在骨肉瘤发病机理中的潜在作用预测了新颖的诊断和治疗策略。
  • DOI:
    10.1038/sj.bjc.6604069
  • 发表时间:
    2007-12-03
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Lee, N;Smolarz, A J;Olson, S;David, O;Reiser, J;Kutner, R;Daw, N C;Prockop, D J;Horwitz, E M;Gregory, C A
  • 通讯作者:
    Gregory, C A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CARL A. GREGORY其他文献

CARL A. GREGORY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CARL A. GREGORY', 18)}}的其他基金

DKK-1,CONTRIBUTES TO THE FORMATION OF BONE LESIONS IN OSTEOSARCOMA
DKK-1,有助于骨肉瘤骨病变的形成
  • 批准号:
    7720779
  • 财政年份:
    2008
  • 资助金额:
    $ 14.42万
  • 项目类别:
DKK-1,CONTRIBUTES TO THE FORMATION OF BONE LESIONS IN OSTEOSARCOMA
DKK-1,有助于骨肉瘤骨病变的形成
  • 批准号:
    7610682
  • 财政年份:
    2007
  • 资助金额:
    $ 14.42万
  • 项目类别:
AGENTS FOR IN VITRO CONTROL OF ADULT STEM CELLS
成体干细胞体外控制剂
  • 批准号:
    7088393
  • 财政年份:
    2006
  • 资助金额:
    $ 14.42万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 14.42万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了